SPIRIT V: A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions.

Trial Profile

SPIRIT V: A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Everolimus (Primary) ; Paclitaxel
  • Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms SPIRIT-V-Diabetic Study
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 01 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Jul 2010 There will be no further follow-up in this trial, as reported by ClinicalTrials.gov.
    • 25 May 2010 Nine-month angiographic and one-year clinical results for the SPIRIT V Diabetic study were presented at EuroPCR 2010 according to an Abbott media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top